University of Miami Miller School of Medicine, Miami, FL
Anuj Shah , Patricia Denise Jones
Background: Cholangiocarcinoma (CCA) is an aggressive cancer with a poor prognosis. However, next-generation sequencing (NGS) of tumors and new mutation-targeted therapies have the potential to greatly improve treatment outcomes while reducing the systemic toxicities of traditional chemotherapy. In this study, we examined clinical characteristics, treatment outcomes and the use of NGS profiling in a diverse South Florida population of CCA patients to identify mutations as potential therapeutic targets. Methods: We included patients treated at Jackson and University of Miami Health Systems who were diagnosed with CCA between 2018 and 2021. Clinical and demographic characteristics were obtained through retrospective chart review and entered into a REDCap database. We analyzed the association between clinical characteristics, treatment outcomes, use of NGS and race/ethnicity using Pearson’s Chi-square and Kruskal Wallis tests. Results: The majority of our sample, n = 140, had intrahepatic CCA (iCCA), n = 97, followed by extrahepatic CCA (eCCA), n = 27, and perihilar CCA (pCCA), n = 16. Stage, based on AJCC 8th edition, was most advanced in iCCA and pCCA; 56% had stage III or higher, compared to only 26.2% of eCCA patients. In addition, the median size of the largest iCCA tumor, 7 cm, was significantly larger than that of pCCA, 2.4 cm, and eCCA, 2.2 cm, p = 0.001. NGS was performed in significantly more iCCA cases, 72.2%, compared to pCCA, 37.5%, and eCCA, 59.3%, p = 0.04. TP53 mutations were most common across all CCA subtypes. Other common mutations included CDKN2A, CDKN2B, ERBB2, KRAS, FGFR2, IDH1, and ARID1A, of which only IDH1 and FGFR2 are targetable mutations. There were no significant differences across CCA subtypes in receipt of targeted therapy; overall, 17.1% of patients received targeted therapy. There were no racial differences in stage at presentation or survival in any CCA subtype. While there were numerical differences in the proportion of patients receiving targeted therapy (13.6% of Black, 12.8% of White, and 21.3% of Hispanic), these differences were not statistically significant. Conclusions: There are significant differences in the presentation of CCA subtypes. Examination of NGS results in a larger sample of CCA patients will help expand knowledge on CCA’s mutational profile and permit examination of potential racial disparities in survival or rates of NGS. This work also highlights the need for further targeted therapies against other common mutations in CCA.
iCCA | pCCA | eCCA | ||
---|---|---|---|---|
Age at diagnosis | 65 | 71.5 | 74 | p = 0.09 |
Percent male | 49.5% | 50% | 63% | p = 0.46 |
Race Black Non-Hispanic White Hispanic Asian/API | 18 (18.6) 29 (29.9) 47 (48.5) 3 (3.1) | 1 (6.3) 2 (12.5) 12 (75) 1 (6.3) | 3 (11.1) 8 (29.6) 16 (59.3) 0 | p = 0.35 |
Percent with cirrhosis | 19.6% | 6.3% | 14.8% | p = 0.4 |
History of prior cholecystectomy | 15.5% | 43.8% | 18.5% | p = 0.03 |
Targeted therapy received | 19.6% | 6.3% | 14.8% | p = 0.4 |
Median survival (days) | 374 | 684 | 383 | p = 0.43 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Parth J Sampat
2023 ASCO Gastrointestinal Cancers Symposium
First Author: Brendon Fusco
2021 ASCO Annual Meeting
First Author: Sung Hwan Lee
2023 ASCO Annual Meeting
First Author: Soniya Abraham